These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 22173527)

  • 1. Assessment of a mandatory tetanus, diphtheria, and pertussis vaccination requirement on vaccine uptake over time.
    Weber DJ; Consoli SA; Sickbert-Bennett E; Rutala WA
    Infect Control Hosp Epidemiol; 2012 Jan; 33(1):81-3. PubMed ID: 22173527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A quality improvement initiative to increase Tdap (tetanus, diphtheria, acellular pertussis) vaccination coverage among direct health care providers at a children's hospital.
    Jiang C; Whitmore-Sisco L; Gaur AH; Adderson EE;
    Vaccine; 2018 Jan; 36(2):214-219. PubMed ID: 29217370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tdap vaccine: current indications for adolescent and adult patients in the United States.
    Kirchner JT
    J Am Osteopath Assoc; 2011 Oct; 111(10 Suppl 6):S7-9. PubMed ID: 22086895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Seasonal influenza and Tdap vaccination policies in Michigan hospitals: progress yet substantial capacity to improve.
    Carlton CA; Sienko DG; Vranesich PA
    Infect Control Hosp Epidemiol; 2013 Mar; 34(3):321-4. PubMed ID: 23388371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse events after administration of tetanus-diphtheria-acellular pertussis vaccine to healthcare workers.
    Sandora TJ; Pfoh E; Lee GM
    Infect Control Hosp Epidemiol; 2009 Apr; 30(4):389-91. PubMed ID: 19239376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety of one dose of diphtheria, tetanus, acellular pertussis and poliomyelitis vaccine (Repevax®) followed by two doses of diphtheria, tetanus and poliomyelitis vaccine (Revaxis®) in adults aged ≥ 40 years not receiving a diphtheria- and tetanus-containing vaccination in the last 20 years.
    Dominicus R; Galtier F; Richard P; Baudin M
    Vaccine; 2014 Jun; 32(31):3942-9. PubMed ID: 24852717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A mandatory campaign to vaccinate health care workers against pertussis.
    Esolen LM; Kilheeney KL
    Am J Infect Control; 2013 Aug; 41(8):740-2. PubMed ID: 23394887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomised, double-blind, non-inferiority clinical trial on the safety and immunogenicity of a tetanus, diphtheria and monocomponent acellular pertussis (TdaP) vaccine in comparison to a tetanus and diphtheria (Td) vaccine when given as booster vaccinations to healthy adults.
    Thierry-Carstensen B; Jordan K; Uhlving HH; Dalby T; Sørensen C; Jensen AM; Heilmann C
    Vaccine; 2012 Aug; 30(37):5464-71. PubMed ID: 22776216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine.
    America Academy of Pediatrics Commitee on Infectious Diseases
    Pediatrics; 2006 Mar; 117(3):965-78. PubMed ID: 16382131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of a tetanus-diphtheria-acellular pertussis vaccine when used off-label in an elderly population.
    Tseng HF; Sy LS; Qian L; Marcy SM; Jackson LA; Glanz J; Nordin J; Baxter R; Naleway A; Donahue J; Weintraub E; Jacobsen SJ;
    Clin Infect Dis; 2013 Feb; 56(3):315-21. PubMed ID: 23196953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary immunization with a triple diphtheria-tetanus-whole cell pertussis vaccine in Iranian infants: an analysis of antibody response.
    Zarei S; Jeddi-Tehrani M; Akhondi MM; Zeraati H; Pourheidari F; Ostadkarampour M; Tavangar B; Shokri F
    Iran J Allergy Asthma Immunol; 2009 Jun; 8(2):85-93. PubMed ID: 19671937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acellular pertussis vaccine boosters combined with diphtheria and tetanus toxoid boosters for adolescents: safety and immunogenicity assessment when preceded by different 5-dose DTaP/DTwP schedules.
    Pichichero ME; Casey JR; Francis AB; Marsocci SM; Murphy M; Hoeger W; Cleary C
    Clin Pediatr (Phila); 2006 Sep; 45(7):613-20. PubMed ID: 16928838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine in adults aged 65 years and older - Advisory Committee on Immunization Practices (ACIP), 2012.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2012 Jun; 61(25):468-70. PubMed ID: 22739778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tetanus and pertussis vaccination coverage among adults aged ≥ 18 years --- United States, 1999 and 2008.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2010 Oct; 59(40):1302-6. PubMed ID: 20948508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Knowledge and attitude factors associated with the prevalence of Tdap (tetanus, diphtheria, and acellular pertussis) booster vaccination in healthcare workers in a large academic hospital in Southern Italy in 2022: a cross-sectional study.
    Mercogliano M; Fiorilla C; Esposito F; Sorrentino M; Mirizzi PD; Parisi A; Tajani A; Buonocore G; Triassi M; Palladino R
    Front Public Health; 2023; 11():1173482. PubMed ID: 37522000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Administration of tetanus, diphtheria, and acellular pertussis vaccine to parents of high-risk infants in the neonatal intensive care unit.
    Dylag AM; Shah SI
    Pediatrics; 2008 Sep; 122(3):e550-5. PubMed ID: 18762489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tetanus-diphtheria-acellular pertussis vaccination of adults in the USA.
    Gidengil CA; Sandora TJ; Lee GM
    Expert Rev Vaccines; 2008 Jul; 7(5):621-34. PubMed ID: 18564017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diphtheria, tetanus, and pertussis: guidelines for vaccine prophylaxis and other preventive measures. Recommendation of the Immunization Practices Advisory Committee. Centers for Disease Control, Department of Health and Human Services.
    Ann Intern Med; 1985 Dec; 103(6 ( Pt 1)):896-905. PubMed ID: 2998252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The safety of immunizing with tetanus-diphtheria-acellular pertussis vaccine (Tdap) less than 2 years following previous tetanus vaccination: Experience during a mass vaccination campaign of healthcare personnel during a respiratory illness outbreak.
    Talbot EA; Brown KH; Kirkland KB; Baughman AL; Halperin SA; Broder KR
    Vaccine; 2010 Nov; 28(50):8001-7. PubMed ID: 20875487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and reactogenicity of a reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine as a single-dose booster in Singaporean adults.
    Chan SH; Tan PT; Han HH; Bock HL
    Singapore Med J; 2006 Apr; 47(4):286-90. PubMed ID: 16572239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.